Key considerations in navigating ticagrelor’s reported effect on heparin-induced thrombocytopenia functional assays in a landscape of limited data

Abstract Purpose This article discusses key considerations regarding ticagrelor’s reported effect on heparin-induced thrombocytopenia functional assays, such as literature gaps and possible management strategies. Summary Limited data indicate that ticagrelor may induce false-negative results in functional assays used in the diagnosis of heparin-induced thrombocytopenia. False-negative functional assays for heparin-induced thrombocytopenia could have catastrophic consequences. The manufacturer labeling of ticagrelor now includes a warning for this potential drug-laboratory interaction. This article suggests areas that would benefit from further research and strategies in navigating this possible interaction. Conclusion Clinicians should exercise caution when evaluating functional assays for heparin-induced thrombocytopenia in patients receiving ticagrelor. This article offers suggestions for future areas of research and potential management strategies.